JPM 2026 44th Annual Healthcare Conference & Biotech Showcase

Flexible solutions for biotech companies at every value inflection point

At Certara, we offer specialized early development services designed to optimize this critical phase of drug development. Our approach combines cutting-edge science and modeling with extensive experience to provide you with a clear, strategic roadmap. From candidate selection and preclinical testing to early clinical trials, our goal is to streamline the process and address potential issues before they become major hurdles.

Certara offers new and emerging biotechs a modern, data-driven approach to drug development. Starting with the end in mind, our cross-functional experts support your team to advance scientific insights, optimize resources, and de-risk your therapy development journey.

• Small molecules, biologics (monoclonal antibodies, ADCs)
• Complex biologics (Bispecific Abs, siRNA, oligonucleotides, radiopharmaceuticals)
• Cell and gene therapies, vaccines, drug-device combos, and devices

Delivering comprehensive support for programs in late discovery and first-in-human studies (FIH):

• Candidate selection, target product profile development & product development strategy
• FIH enabling activity planning & stewardship
• Pre-IND strategy, briefing document support, IND writing & submission
• FIH execution & reporting

By partnering with Certara, you gain access to a team of cross-functional experts who use advanced modeling and simulation techniques to predict drug behavior and outcomes. This helps in making informed decisions, reducing the risk of late-stage failures, and accelerating the time to market. Essentially, our services help you navigate the complexities of early development with confidence and access to the right expertise at the right time.

• Certara’s Strategic Early Development Solutions
• “要从哪里开始？”：选择首次人体临床试验的起始剂量
• How the Simcyp® Discovery Simulator will Accelerate Early Drug Development
• Our Factsheet